Based on drugs, the market includes biguanides, alpha-glucosidase inhibitors, dopamine-D2 receptor agonists, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors, sulfonylureas, and meglitinides.
DPP-4 inhibitors segment held the largest market share in 2019. The Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors segment of the oral anti-diabetes drug market was valued at more than USD 7 million in 2019, and it is expected to record a CAGR lesser than 4% during the forecast period (2019-2025). DPP-4 inhibitor drugs are gaining momentum in the market because the products do not seem to have any effect on primary adverse cardiovascular outcomes and risk for heart failure. Besides, they can be used both as a combination therapy with insulin, sulphonylureas, and dipeptidyl peptidase-4 drugs and as a monotherapy, thus, making it a widely used class of drugs. During the forecast period, the DPP-4 inhibitors segment is expected to witness constant growth rate, due to the introduction of new drugs that have improved efficacy, like glucagon-like peptide (GLP-1) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. The segment is still expected to maintain the largest market share among all oral anti-diabetes drugs market segments.
Asia-Pacific leading the oral anti-diabetes drugs market. Currently, North America holds the major share in the oral anti-diabetes drugs market. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period. This is due to the high prevalence of diabetes in this region, which caused consequent adverse health and economic consequences. The rates of newly diagnosed cases of Type 1 and Type 2 diabetes are increasing among the youth in the Asia-Pacific region. In 2019, China and India, around 123.6 million people and 76.79 million people, respectively, are living with diagnosed diabetes. Moreover, an increase in the launch of new drugs with improved efficacy and high reimbursement for medicines is expected to have a positive impact on the oral anti-diabetes drug market. The increasing incidence and prevalence of diabetes and the increasing healthcare expenditure in the Asia-Pacific countries are an indication of the increasing usage of oral anti-diabetes drugs.
Top Major Players
The oral anti-diabetes drug market is consolidated, with few major manufacturers having a global market presence, while the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs. For instance, Oramed is performing research on the new molecule ORMD-0801, which is the first oral insulin capsule that has the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets. The major players are Eli Lilly, J&J, Astellas Pharma, AstraZeneca and Sanofi.